Geneius is developing a series of cancer products utilizing a proprietary Cyto-toxic T Lymphocyte (CTL) platform which rebalances the immune system to actively reject and reinstate protective immuno-surveillance to tumors.

Geneius is leveraging an innovative business model to pursue this opportunity. Geneius is both a development outsourcing organization and an investment fund which is working with Academia, Pharmaceutical Partners and Financial Investors through a innovative business model that is transformative for the Biotech Industry.

Geneius has licensed and filed patents for key technologies and is building its team. It has been holding initial marketing and financing discussions with pharmaceutical companies, government agencies and investors